BNP and NT-proBNP Global Market Opportunities and Strategies to 2035

This report describes and explains the BNP and NTproBNP market and covers 2020-2025, termed the historic period, and 2025-2030, 2035F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.

The global BNP and NTproBNP market reached a value of nearly $2.26 billion in 2025, having grown at a compound annual growth rate (CAGR) of 12.7% since 2020. The market is expected to grow from $2.26 billion in 2025 to $3.89 billion in 2030 at a rate of 11.5%. The market is then expected to grow at a CAGR of 10.2% from 2030 and reach $6.33 billion in 2035.

Growth in the historic period resulted from increased healthcare expenditure, expansion of healthcare infrastructure, expansion of private diagnostic laboratories and rising awareness of early diagnosis and preventive cardiology. Factors that negatively affected growth in the historic period were high testing costs and limited healthcare access in developing regions.

Going forward, rising aging population, rising prevalence of cardiovascular disorders, increasing adoption of point-of-care cardiac testing and increasing emergency department utilization will drive the growth. Factors that could hinder the growth of the BNP and NTproBNP market in the future include reimbursement challenges, lack of standardization in testing and impact of trade wars and tariffs.

Market trends for the BNP and NTproBNP market include introduction of rapid screening bioassays to strengthen their competitive position.

The BNP and NTproBNP market is segmented by type into BNP (Brain Natriuretic Peptide) and NT-proBNP (N-terminal Pro-B-Type Natriuretic Peptide). The NT-proBNP (N-terminal Pro-B-Type Natriuretic Peptide) market was the largest segment of the BNP and NTproBNP market segmented by type, accounting for 64% or $1.44 billion of the total in 2025. Going forward, the BNP (Brain Natriuretic Peptide) segment is expected to be the fastest-growing segment in the BNP and NTproBNP market segmented by type, at a CAGR of 12.6% during 2025-2030.

The BNP and NTproBNP market is segmented by location of testing into point of care testing and laboratory testing. The point of care testing was the largest segment of the BNP and NTproBNP market segmented by location of testing, accounting for 62.8% or $1.42 billion of the total in 2025. Going forward, the point of care testing segment is expected to be the fastest-growing segment in the BNP and NTproBNP market segmented by location of testing, at a CAGR of 12.4% during 2025-2030.

The BNP and NTproBNP market is segmented by application into myocardial infarction, congestive heart failure, acute coronary syndrome (ACS) and other applications. The myocardial infarction market was the largest segment of the BNP and NTproBNP market segmented by application, accounting for 37.2% or $844.3 million of the total in 2025. Going forward, the congestive heart failure segment is expected to be the fastest-growing segment in the BNP and NTproBNP market segmented by application, at a CAGR of 13% during 2025-2030.

North America was the largest region in the BNP and NTproBNP market, accounting for 40.2% or $909.9 million of the total in 2025. It was followed by Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the BNP and NTproBNP market will be Asia Pacific and Western Europe where growth will be at CAGRs of 13.9% and 12.3% respectively. These will be followed by North America and Middle East where the markets are expected to grow at CAGRs of 10.5% and 9.8% respectively.

The global BNP and NTproBNP market is fairly concentrated, with large players operating in the market. The top 10 competitors in the market made up 34.5% of the total market in 2024. Abbott Laboratories was the largest competitor with a 4.2% share of the market, followed by F Hoffman La Roche Ltd. with 4.1%, Siemens Healthineers with 3.9%, bioMérieux SA with 3.7%, QuidelOrtho Corp. with 3.5%, Beckman Coulter (Danaher) with 3.2%, Randox Laboratories Ltd. with 3.1%, Bio-Techne Co. with 3%, Getein Biotech Inc. with 2.9% and Tosoh Corporation with 2.8%.

The top opportunities in the BNP and NTproBNP market segmented by type will arise in the BNP (Brain Natriuretic Peptide) segment, which will gain $1.63 billion of global annual sales by 2030. The top opportunities in the BNP and NTproBNP market segmented by location of testing will arise in the point of care testing segment, which will gain $1.12 billion of global annual sales by 2030. The top opportunities in the BNP and NTproBNP market segmented by application will arise in the myocardial infarction segment, which will gain $615.3 million of global annual sales by 2030. The BNP and NTproBNP market size will gain the most in the USA at $517.5 million.

Player-adopted strategies in the BNP and NTproBNP market include focus on focuses on the new launches, focus on enhancing its operational capabilities through new developments and strengthening their business expertise through strategic expansions.

To take advantage of the opportunities, the analyst recommends the BNP and NTproBNP companies to focus on rapid screening bioassay innovation and strategic partnerships, focus on BNP segment for high growth and acute care expansion, focus on point of care testing for rapid growth and decentralized care expansion, focus on expanding distribution through integrated clinical and digital channels, focus on value-based tiered pricing to expand adoption and sustain margins, focus on clinical education to drive adoption and trust, focus on integrated multi-channel promotion to expand reach, focus on congestive heart failure segment for sustained growth.

This product will be delivered within 3-5 business days.